Literature DB >> 23677903

Association between baseline fetal hemoglobin levels and incidence of severe vaso-occlusive pain episodes in children with sickle cell anemia.

Pallav Bhatnagar1, Jeffrey R Keefer, James F Casella, Emily A Barron-Casella, Christopher J Bean, Craig W Hooper, Amanda B Payne, Dan E Arking, Michael R Debaun.   

Abstract

The ameliorating effect of high fetal hemoglobin (HbF) levels on the incidence of pain episodes in sickle cell anemia (SCA) is well-known; however, in children this relationship is less clearly established. We hypothesized that higher HbF levels in children with SCA are associated with fewer severe pain episodes. A meta-analysis of data from the Silent Infarct Transfusion Trial (n = 456) and the Cooperative Study of Sickle Cell Disease (n = 764), demonstrated that baseline HbF levels were associated with the incidence of severe pain, commonly defined across studies as an event requiring hospitalization (P-value = 0.02).
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  fetal hemoglobin; sickle cell anemia; vaso-occlusive pain

Mesh:

Substances:

Year:  2013        PMID: 23677903      PMCID: PMC4387562          DOI: 10.1002/pbc.24588

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  14 in total

1.  The cooperative study of sickle cell disease: review of study design and objectives.

Authors:  M Gaston; W F Rosse
Journal:  Am J Pediatr Hematol Oncol       Date:  1982

2.  Design of the silent cerebral infarct transfusion (SIT) trial.

Authors:  James F Casella; Allison A King; Bruce Barton; Desiree A White; Michael J Noetzel; Rebecca N Ichord; Cindy Terrill; Deborah Hirtz; Robert C McKinstry; John J Strouse; Thomas H Howard; Thomas D Coates; Caterina P Minniti; Andrew D Campbell; Bruce A Vendt; Harold Lehmann; Michael R Debaun
Journal:  Pediatr Hematol Oncol       Date:  2010-03       Impact factor: 1.969

3.  Pain in sickle cell disease. Rates and risk factors.

Authors:  O S Platt; B D Thorington; D J Brambilla; P F Milner; W F Rosse; E Vichinsky; T R Kinney
Journal:  N Engl J Med       Date:  1991-07-04       Impact factor: 91.245

4.  Sickle cell disease subphenotypes in patients from Southwestern Province of Saudi Arabia.

Authors:  Abdulrahman Alsultan; Aamer Aleem; Hazem Ghabbour; Farjah H AlGahtani; Ali Al-Shehri; Mohamed Elfaki Osman; Kadijah Kurban; Mohammed S Alsultan; Hasan Bahakim; AbdelKareem M Al-Momen
Journal:  J Pediatr Hematol Oncol       Date:  2012-03       Impact factor: 1.289

Review 5.  Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.

Authors:  Sophie Lanzkron; John J Strouse; Renee Wilson; Mary Catherine Beach; Carlton Haywood; HaeSong Park; Catherine Witkop; Eric B Bass; Jodi B Segal
Journal:  Ann Intern Med       Date:  2008-05-05       Impact factor: 25.391

6.  Definitions of the phenotypic manifestations of sickle cell disease.

Authors:  Samir K Ballas; Susan Lieff; Lennette J Benjamin; Carlton D Dampier; Matthew M Heeney; Carolyn Hoppe; Cage S Johnson; Zora R Rogers; Kim Smith-Whitley; Winfred C Wang; Marilyn J Telen
Journal:  Am J Hematol       Date:  2010-01       Impact factor: 10.047

7.  Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood.

Authors:  M C Stevens; R J Hayes; S Vaidya; G R Serjeant
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

8.  Mortality in sickle cell disease. Life expectancy and risk factors for early death.

Authors:  O S Platt; D J Brambilla; W F Rosse; P F Milner; O Castro; M H Steinberg; P P Klug
Journal:  N Engl J Med       Date:  1994-06-09       Impact factor: 91.245

9.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors:  S Charache; M L Terrin; R D Moore; G J Dover; F B Barton; S V Eckert; R P McMahon; D R Bonds
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

10.  The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease.

Authors:  O Castro; D J Brambilla; B Thorington; C A Reindorf; R B Scott; P Gillette; J C Vera; P S Levy
Journal:  Blood       Date:  1994-07-15       Impact factor: 22.113

View more
  2 in total

1.  A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.

Authors:  Jeremie H Estepp; Matthew P Smeltzer; Guolian Kang; Chen Li; Winfred C Wang; Christina Abrams; Banu Aygun; Russell E Ware; Kerri Nottage; Jane S Hankins
Journal:  Am J Hematol       Date:  2017-09-28       Impact factor: 10.047

2.  Peptide nucleic acids targeting β-globin mRNAs selectively inhibit hemoglobin production in murine erythroleukemia cells.

Authors:  Giulia Montagner; Chiara Gemmo; Enrica Fabbri; Alex Manicardi; Igea Accardo; Nicoletta Bianchi; Alessia Finotti; Giulia Breveglieri; Francesca Salvatori; Monica Borgatti; Ilaria Lampronti; Alberto Bresciani; Sergio Altamura; Roberto Corradini; Roberto Gambari
Journal:  Int J Mol Med       Date:  2014-11-14       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.